Xenon to present at the 44th Annual J.P. Morgan Healthcare Conference. VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) - Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026. | Date: | Monday, January 12, 2026 | | Time: | 9:00-9:40am Pacific Time (12:00-12:40pm Eastern Time) | | Webcast: | Webcast - 44th Annual J.P. Morgan Healthcare Conference | | Presenter: | Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals | | / | / | A live audio webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Na[V] 1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow Xenon Pharmaceuticals Inc. on LinkedIn and X. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner. Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical studies; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of its and its partners' product candidates; the efficacy of its clinical study designs; its ability to successfully develop and achieve milestones in its azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of its interactions with regulators; its ability to successfully develop and obtain regulatory approval of azetukalner and its other product candidates; and anticipated timing of topline data readout from its clinical studies of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond its control, include, but are not limited to: clinical studies may not demonstrate safety and efficacy of any of its or its collaborators' product candidates; promising results from pre-clinical development activities or early clinical study results may not be replicated in later clinical studies; its assumptions regarding its planned expenditures and sufficiency of its cash to fund operations may be incorrect; its ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of its or its collaborators' product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Xenon Pharmaceuticals Inc. may not achieve additional milestones in its proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical studies; the impact of market, industry, and regulatory conditions on clinical study enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in its filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and Xenon Pharmaceuticals Inc. assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Xenon announces appointment of Darren Cline as Chief Commercial Officer.